BACKGROUND: Puumala hantavirus (PUUV) induces an acute tubulointerstitial nephritis and acute kidney injury (AKI). Our aim was to evaluate the prognosis of severe AKI associated with PUUV infection. METHODS: We examined 556 patients who were treated at Tampere University Hospital during 1982-2013 for acute, serologically confirmed PUUV infection. Plasma creatinine was measured during hospitalization, convalescence, and 1, 2, and 5 years after the acute infection. RESULTS: Plasma creatinine concentration was elevated (>100 μmol/l) in 459 (83%) patients, while altogether 189 patients (34%) had severe AKI defined as Kidney Disease: Improving Global Outcomes (KDIGO) stage 3, that is, plasma creatinine ≥353.6 μmol/l (4.0 mg/dl) or need of dialysis. There were no fatal cases during the hospitalization or the following 3 months. Fatality rate during the years following PUUV infection did not differ between patients who had suffered from severe AKI versus those without severe AKI. Post-hospitalization plasma creatinine values were available for 188 (34%) patients. One month after the acute infection, patients with prior severe AKI had higher median plasma creatinine concentration (82 µmol/l, range 54-184) than patients without severe AKI (74 µmol/l, range 55-109, p = 0.005). After 1 year, no significant difference existed in median plasma creatinine concentrations between patients with (71 µmol/l, range 36-123) and without prior severe AKI (72 µmol/l, range 34-116, p = 0.711). After 5 years all but 1 patient had normal creatinine levels. CONCLUSIONS: In contrast to the worldwide well-accepted KDIGO criteria, severe AKI associated with PUUV infection is not associated with excess fatality but has a very good prognosis, both in the short and long terms. 2015 S. Karger AG, Basel.
BACKGROUND:Puumala hantavirus (PUUV) induces an acute tubulointerstitial nephritis and acute kidney injury (AKI). Our aim was to evaluate the prognosis of severe AKI associated with PUUV infection. METHODS: We examined 556 patients who were treated at Tampere University Hospital during 1982-2013 for acute, serologically confirmed PUUV infection. Plasma creatinine was measured during hospitalization, convalescence, and 1, 2, and 5 years after the acute infection. RESULTS: Plasma creatinine concentration was elevated (>100 μmol/l) in 459 (83%) patients, while altogether 189 patients (34%) had severe AKI defined as Kidney Disease: Improving Global Outcomes (KDIGO) stage 3, that is, plasma creatinine ≥353.6 μmol/l (4.0 mg/dl) or need of dialysis. There were no fatal cases during the hospitalization or the following 3 months. Fatality rate during the years following PUUV infection did not differ between patients who had suffered from severe AKI versus those without severe AKI. Post-hospitalization plasma creatinine values were available for 188 (34%) patients. One month after the acute infection, patients with prior severe AKI had higher median plasma creatinine concentration (82 µmol/l, range 54-184) than patients without severe AKI (74 µmol/l, range 55-109, p = 0.005). After 1 year, no significant difference existed in median plasma creatinine concentrations between patients with (71 µmol/l, range 36-123) and without prior severe AKI (72 µmol/l, range 34-116, p = 0.711). After 5 years all but 1 patient had normal creatinine levels. CONCLUSIONS: In contrast to the worldwide well-accepted KDIGO criteria, severe AKI associated with PUUV infection is not associated with excess fatality but has a very good prognosis, both in the short and long terms. 2015 S. Karger AG, Basel.
Authors: Felix C Koehler; Veronica Di Cristanziano; Martin R Späth; K Johanna R Hoyer-Allo; Manuel Wanken; Roman-Ulrich Müller; Volker Burst Journal: Clin Kidney J Date: 2022-01-29
Authors: Anna Papa; Antti Vaheri; James W LeDuc; Detlev H Krüger; Tatjana Avšič-Županc; Jiro Arikawa; Jin-Won Song; Alemka Markotić; Jan Clement; Mifang Liang; Dexin Li; Liudmila N Yashina; Colleen B Jonsson; Connie S Schmaljohn Journal: Antiviral Res Date: 2016-08-17 Impact factor: 5.970
Authors: J Clement; A P K Lee; G A Verpooten; L Laenen; V Vergote; H De Samblanx; Z N Berneman; M Van Ranst; P Maes Journal: Eur J Clin Microbiol Infect Dis Date: 2017-10-06 Impact factor: 3.267
Authors: Paula S Mantula; Tuula K Outinen; Pia Jaatinen; Mari Hämäläinen; Heini Huhtala; Ilkka H Pörsti; Antti Vaheri; Jukka T Mustonen; Satu M Mäkelä Journal: PLoS One Date: 2018-12-05 Impact factor: 3.240
Authors: Jan Clement; James W LeDuc; Graham Lloyd; Jean-Marc Reynes; Lorraine McElhinney; Marc Van Ranst; Ho-Wang Lee Journal: Viruses Date: 2019-07-17 Impact factor: 5.048